Best Trinity County Grants for Nonprofits in California

The DoW Spinal Cord Injury Translational Research Award supports innovative research to transform promising spinal cord injury findings into clinical applications. It features an Early-Career Partnership Option, requiring at least one early-career principal investigator. Collaborations with SCI community partners are essential for providing guidance throughout the project. This funding opportunity aims to enhance the effectiveness of spinal cord injury interventions and improve patient outcomes.

The FY26 Spinal Cord Injury Research Program Clinical Translation Research Award funds innovative clinical research aimed at bridging the gap to larger clinical trials. It focuses on accelerating the application of new techniques and improving patient outcomes through effective diagnosis and rehabilitation strategies. Key features include an Early-Career Partnership Option for principal investigators and a requirement for community partner involvement, ensuring collaborative research that meets real-world needs.

The FY26 Spinal Cord Injury Research Program Clinical Trial Award supports innovative clinical trials aimed at significantly improving spinal cord injury treatment. This funding opportunity encourages collaboration by allowing two Principal Investigators, including an early-career investigator, to drive the research forward. Applicants must partner with at least two SCI community members, ensuring that the project is informed by lived experiences and community needs throughout its development and implementation.

The FY26 Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA) supports innovative research aimed at enhancing patient care and quality of life for individuals with spinal cord injuries. This award encourages collaboration, allowing an Early-Career Partnership Option for two Principal Investigators, where one must be an early-career investigator. Focused on impactful research from basic to translational science, this opportunity is crucial for advancing SCI knowledge and interventions.

The FY26 Lung Cancer Research Program's Idea Development Award supports innovative, high-risk research aimed at significant breakthroughs in lung cancer treatment. It encourages new concepts in their early stages, requiring preliminary data to demonstrate feasibility, although not necessarily from lung cancer studies. This program also features a New Investigator category, allowing early-career researchers to compete separately for funding, fostering a diverse range of impactful investigations.

The Lung Cancer Patient-Centered Outcomes and Survivorship Award (PCOSA) aims to enhance health outcomes for lung cancer patients by promoting patient-centered research. This FY26 initiative encourages projects that address key areas of survivorship and requires the involvement of lung cancer survivors or caregivers in research teams. Additionally, it supports both translational and clinical research, including pilot clinical trials, to improve the overall patient experience.

The Lung Cancer Translational Research Award (TRA) for FY26 supports innovative translational research aimed at transforming promising lung cancer ideas into clinical applications. This award emphasizes advanced preclinical studies and pilot clinical trials of novel interventions, addressing critical research areas within the Lung Cancer Research Program. Applicants can choose between two funding levels to advance their impactful studies, thereby contributing to significant advancements in lung cancer treatment.

The FY26 Melanoma Research Program Focused Program Award for Rare Melanomas supports multidisciplinary research initiatives aimed at addressing critical questions in rare melanomas. This award requires collaboration between an Initiating Principal Investigator and up to two Partnering PIs, with the inclusion of a rare melanoma survivor or patient advocate in the project team. Approximately $5.6M is allocated to fund two awards, each capped at $2.8M, over a maximum performance period of four years.

The Melanoma Research Program Melanoma Academy Scholar Award supports early career investigators within seven years of their initial faculty appointment. This unique virtual academy fosters collaboration among established researchers and Scholars, focusing on research and career potential in melanoma. With approximately $1.54M allocated to fund two Scholar Awards, each capped at $0.77M, the maximum performance period is three years, and funding is expected to be available until September 30, 2032.

The FY26 Melanoma Research Program Survivorship Research Award aims to enhance the well-being of melanoma survivors through innovative research. This funding opportunity supports studies that prioritize quality of life, involving melanoma survivors or their families as collaborators. With approximately $2.04M available, two awards of up to $1.02M each will be granted for research over a maximum period of three years. Applications must be submitted by September 30, 2027, to be funded with FY26 resources.

The FY26 Melanoma Research Program Idea Award encourages innovative and high-risk research to advance melanoma treatment. With a budget of approximately $5.6M for 10 awards, each grant can fund up to $0.56M over a maximum of 2 years. The program aims to support projects that establish proof of principle and generate preliminary data for future funding opportunities. Notably, preliminary data is discouraged, and applicants must receive an invitation to submit a full application after the pre-application stage.

The FY26 Melanoma Research Program Team Science Award promotes collaborative, hypothesis-driven research to enhance melanoma care. This funding supports multidisciplinary teams of two to three Principal Investigators (PIs) to tackle complex challenges in melanoma. With approximately $18.9M available, the program aims to fund nine projects with a maximum of $2.1M per award over three years. Awards will be made by September 30, 2027, using FY26 funds that expire on September 30, 2032.

The FY26 Military Burn Research Program (MBRP) Technology/Therapeutic Development Award (TTDA) aims to translate promising preclinical findings into burn products for clinical use in challenging environments. This award supports the development of both tangible products, like medical devices, and knowledge products that enhance health outcomes. A new Mentorship Option encourages collaboration between experienced researchers and junior scientists, fostering the next generation of leaders in military burn care research.

The FY26 Military Burn Research Program (MBRP) Discovery Award aims to support groundbreaking research in combat-relevant burn care. This award encourages innovative and exploratory studies that provide new insights and foundational data for future clinical research. The focus is on novel approaches that lay the groundwork for scientific advancements and product development in burn care, ensuring robust preliminary data generation for subsequent research initiatives.

The DoW Military Burn, Patient-Centered Research Award aims to enhance the implementation of burn care research into clinical practice for military settings. The FY26 program supports clinical trials and research that directly benefit burn patients in resource-limited environments, fostering collaborations between experienced researchers and junior scholars. This initiative addresses critical gaps in combat burn care, ensuring effective interventions and guidelines are developed and utilized in operational battlespaces.

The DoW Prostate Cancer Idea Development Award for fiscal year 2026 supports innovative research ideas that address the Prostate Cancer Research Program's overarching challenges. This award emphasizes new investigators within 10 years of their terminal degree, encouraging collaboration with experienced researchers in the field. By fostering unique approaches to prostate cancer research, the program aims to make significant contributions to advancing understanding and treatment of this disease.

The FY26 Prostate Cancer Research Program (PCRP) Early Investigator Research Award supports early-career researchers focusing on prostate cancer. Eligible applicants must possess a doctoral degree and less than three years of postdoctoral experience. Each application requires a mentorship component, ensuring guidance from an experienced researcher, along with a detailed development plan outlining the skills and expertise necessary for project completion and career advancement. This award addresses critical challenges in prostate cancer research.

The FY26 Prostate Cancer Research Program (PCRP) Physician Research Award supports early-career clinician investigators in their transition to prostate cancer research. Applicants must include a mentor with relevant experience and outline a personalized development plan aimed at acquiring essential research skills. The award encourages innovative approaches to addressing the program's overarching challenges, ultimately enhancing the career trajectories of participating physicians in this critical field.

The Ovarian Cancer Clinical Trial Academy (OCCTA) supports Early-Career Investigators (ECIs) in clinical trial research aimed at effective ovarian cancer treatments. It provides essential mentoring, networking, and skill development needed for executing clinical trials. The FY26 funding will specifically support translational research and early-phase trials, requiring preliminary data and a commitment of at least 25% effort from the ECI. Mentorship is vital, with a focus on experienced clinical trialists guiding ECIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.

The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award aims to support impactful research addressing critical needs in ovarian cancer and patient care. It requires a robust research plan with preliminary data and allows for studies across all research phases, excluding clinical trials. A unique Partnering Principal Investigator option encourages collaboration between two PIs to enhance research outcomes beyond individual efforts, promoting innovation in the field of ovarian cancer.

The DoW Ovarian Cancer Pilot Award fosters innovative research that challenges existing paradigms in ovarian cancer. It aims to propel groundbreaking discoveries and advancements in the field. Notably, the award prioritizes originality over scientific merit alone, ensuring that innovative ideas are at the forefront. The application process includes a blinded pre-application screening to maintain confidentiality and integrity, encouraging fresh perspectives in ovarian cancer research.

The FY26 Breast Cancer Research Program's Transformative Breast Cancer Consortium Award fosters significant collaborations that aim to revolutionize care for individuals affected by breast cancer. This award supports a multidisciplinary consortium of leading scientists, clinicians, and advocates to tackle major challenges in breast cancer research. Proposals must address at least one of the program's overarching challenges and demonstrate a transformative impact that cannot be achieved by individual investigators alone.

The FY26 Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) aims to enhance drug discovery and therapeutic development for hearing restoration following military-related auditory injuries. The award supports preclinical and clinical studies aligned with HRRP focus areas. It features two funding levels, including a Partnering Principal Investigator option, and evaluates proposals based on research rationale, strategy, impact, and personnel. Notably, it excludes funding for clinical trials, tinnitus, and vestibular research.

Geological Society of America 

The Geological Society of America (GSA), founded in 1888, is a global scientific society with members from academia, government, and industry in more than 100 countries. Through its meetings, publications, and programs, GSA enhances the professional growth of geoscientists at all career levels, encourages cooperative research among earth, life, planetary, and social scientists, fosters public dialogue on geoscience issues, and promotes the geosciences in the service of humankind. GSA is headquartered in Boulder, Colorado, USA.

Jack Kleinman Memorial Award for Volcano Research

The Jack Kleinman Memorial Award for Volcano Research represents a partnership between GSA and the U.S. Geological Survey (USGS) to recognize early-career scientists conducting high-impact research in volcanology. The award was created in memory of Jack Kleinman—a USGS Cascades Volcano Observatory scientist known for his commitment to collecting high-quality field data and who relished a challenge, inspired enthusiasm in others, and delighted in the natural world. The award honors students who demonstrate these same qualities in their scientific explorations.

Up to US$5,000 may be awarded to undergraduate, graduate, and aspiring graduate students, regardless of current enrollment status. Successful proposals typically focus on geologic, geochemical, geophysical, or hazards investigations with an emphasis on fieldwork. Cooperation with a staff member from the USGS Volcano Science Center is encouraged and given considerable weight in the selection process.

Funding is intended to defray the costs of field-focused studies, such as travel to field sites, living expenses during fieldwork, field supplies, and analytical costs. Awardees are invited to present their results in the USGS Kleinman Seminar Series and attend the Awards Ceremony at the GSA annual meeting.

Investing in research and healthcare to prevent, treat, and heal firearm-related harms

Kaiser Permanente Center for Gun Violence Research and Education

Kaiser Permanente established this Center in 2022 to scale its longstanding commitment to help communities prevent, treat, and heal from firearm-related injuries or death. The Center’s focus on violence prevention is rooted in healthcare, care delivery, and clinical interventions.

The Center is coordinated in collaboration with the Health Alliance for Violence Intervention (HAVI).

Research to support more effective health interventions

The Center funds research to test and expand health interventions that treat and prevent firearm injuries and deaths. This approach uses the same rigor and expertise that has helped treat and prevent other leading health concerns and causes of death, such as stroke, cancer, and heart disease. Funding supports projects to:

• Identify and evaluate health system strategies to address firearm injury and death, especially in communities that are most impacted.
• Test clinical interventions to prevent, treat, and heal trauma caused by firearm injuries and death.
• Assess pathways to implement and scale clinical interventions for firearm injury prevention in various healthcare settings.
• Improve healthcare identification and engagement of individuals at high risk of firearm injury or death.

Since its inception, the Center has awarded more than $8.5 million through 49 grants across 25 states and Washington, D.C., to advance research, capacity building, narrative change, and education.

Funding Opportunity

The call is open to applicants at varying stages of the research continuum. It is expected that central to all proposed initiatives are efforts to meaningfully engage communities that have been the most impacted by firearm violence.

What Work Will Be Considered for Funding?

Funding is currently available in two categories: Category 1 - Research Capacity Building; Category 2 - Pilot or Formative Healthcare Research

Category 1: Research Capacity Building

Up to two (2) projects will be selected, each receiving up to $100,000 over two (2) years.

Build capacity within the organization, institution, and/or clinical care setting to conduct research on healthcare approaches to addressing firearm violence or firearm suicide.